Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2 years.
Generally in good health.
Subject must read and write at a level sufficient to provide written informed consent.
You may not be if
Current or past history of seizure disorder.
Subject has a primary diagnosis or received treatment for panic disorder, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder.
Currently using illicit drugs or other psychotropic drugs.
Patient poses a current suicidal risk or has attempted suicide in the past 6 months.